Cytomegalovirus-induced salivary gland pathology: AREG, FGF8, TNF-α, and IL-6 signal dysregulation and neoplasia

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 386-397

  Melnick, Michael ^a   Deluca, Krysta A ^a   Sedghizadeh, Parish P ^b   Jaskoll, Tina ^a  

^a School of Pharmacy   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AREG; CMV induced pathology; Cytomegalovirus; FGF8; IL 6; Salivary gland; TNF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ACICLOVIR; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; HOST CELL; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MONOTHERAPY; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SALIVARY GLAND CARCINOMA; TUMOR REGRESSION; UPREGULATION; VIRUS LOAD; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; CARCINOMA, MUCOEPIDERMOID; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLAST GROWTH FACTOR 8; GLYCOPROTEINS; HERPESVIRIDAE INFECTIONS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MUROMEGALOVIRUS; ORGAN CULTURE TECHNIQUES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBMANDIBULAR GLAND; SUBMANDIBULAR GLAND NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84874765888     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.01.005     Document Type: Article

References (57)

1. Akrish S., Peled M., Ben-Izhak B., Nagler R.M. Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncology 2009, 45:1044-1050.
2. Alwine J.C. The human cytomegalovirus assembly compartment: a masterpiece of viral manipulation of cellular processes that facilitates assembly and egress. PLoS Pathogens 2012, 8:e1002878.
3. Azevedo A., Cunha V., Teixeira A.L., Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World Journal of Clinical Oncology 2011, 2:384-396.
4. Becker D., Sfakianakis I., Krupp M., Staib F., Gerhold-Ay A., Victor A., Binder H., Blettner M., Maass T., Thorgeirsson S., Galle P.R., Teufel A. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Molecular Cancer 2012, 11:55.
5. Bell D., Hanna E.Y. Salivary gland cancers: biology and molecular targets for therapy. Current Oncology Reports 2012, 14:166-174.
6. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
7. Boppana S.B., Fowler K.B. Persistence in the Population: Epidemiology and Transmission 2007, Cambridge University Press, Cambridge, Mass.
8. Burns W.H., Wingard J.R., Bender W.J., Saral R. Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus. Journal of Virology 1981, 39:889-893.
9. Chalancon G., Kruse K., Babu M.M. Cell biology. Reconfiguring regulation. Science 2012, 335:1050-1051.
10. Fuzzy Logic and Neural Network Handbook 1996, McGraw-Hill, New York. C. Chen (Ed.).
11. Elo T.D., Valve E.M., Seppänen J.A., Vuorikoski H.J., Mäkelä S.I., Poutanen M., Kujala P.M., Härkönen P.L. Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia 2010, 12:915-927.
12. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics and Development 2008, 18:73-79.
13. Ettl T., Stiegler C., Zeitler K., Agaimy A., Zenk J., Reichert T.E., Gosau M., Kühnel T., Brockhoff G., Schwarz S. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Human Pathology 2012, 43:921-931.
14. Gillespie M.B., Albergotti W.G., Eisele D.W. Recurrent salivary gland cancer. Current Treatment Options in Oncology 2012, 13:58-70.
15. Goldberg D.E. Genetics Algorithms in Search, Optimization, and Machine Learning 1989, Addison-Wesley, Reading, Mass.
16. Gulbahce N., Yan H., Dricot A., Padi M., Byrdsong D., Franchi R., Lee D.S., Rozenblatt-Rosen O., Mar J.C., Calderwood M.A., Baldwin A., Zhao B., Santhanam B., Braun P., Simonis N., Huh K.W., Hellner K., Grace M., Chen A., Rubio R., Marto J.A., Christakis N.A., Kieff E., Roth F.P., Roecklein-Canfield J., Decaprio J.A., Cusick M.E., Quackenbush J., Hill D.E., Münger K., Vidal M., Barabási A.L. Viral perturbations of host networks reflect disease etiology. PLoS Computational Biology 2012, 8:e1002531.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Ito F.A., Coletta R.D., Graner E., de Almeida O.P., Lopes M.A. Salivary gland tumors: immunohistochemical study of EGF, EGFR, ERbB-2, FAS and Ki-67. Analytical and Quantitative Cytology and Histology 2009, 31:280-287.
19. Jaskoll T., Melnick M. Submandibular gland morphogenesis: stage-specific expression of TGF-alpha/EGF, IGF, TGF-beta, TNF, and IL-6 signal transduction in normal embryonic mice and the phenotypic effects of TGF-beta2, TGF-beta3, and EGF-r null mutations. Anatomical Record 1999, 256:252-268.
20. Jaskoll T., Zhou Y.M., Chai Y., Makarenkova H.P., Collinson J.M., West J.D., Hajihosseini M.K., Lee J., Melnick M. Embryonic submandibular gland morphogenesis: stage-specific protein localization of FGFs, BMPs, Pax6 and Pax9 in normal mice and abnormal SMG phenotypes in FgfR2-IIIc(+/Delta), BMP7(-/-) and Pax6(-/-) mice. Cells, Tissues, Organs 2002, 170:83-98.
21. Jaskoll T., Witcher D., Toreno L., Bringas P., Moon A.M., Melnick M. FGF8 dose-dependent regulation of embryonic submandibular salivary gland morphogenesis. Developmental Biology 2004, 268:457-469.
22. Jaskoll T., Htet K., Abichaker G., Kaye F.J., Melnick M. CRTC1 expression during normal and abnormal salivary gland development supports a precursor cell origin for mucoepidermoid cancer. Gene Expression Patterns 2011, 11:57-63.
23. Jullien J., Gurdon J. Morphogen gradient interpretation by a regulated trafficking step during ligand-receptor transduction. Genes & Development 2005, 19:2682-2694.
24. Karin M., C.Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews. Cancer 2002, 2:301-310.
25. Kashimata M., Sayeed S., Ka A., Onetti-Muda A., Sakagami H., Faraggiana T., Gresik E.W. The ERK-1/2 signaling pathway is involved in the stimulation of branching morphogenesis of fetal mouse submandibular glands by EGF. Developmental Biology 2000, 220:183-196.
26. Koch C. Systems biology. Modular biological complexity. Science 2012, 337:531-532.
27. Koyama N., Kashimata M., Sakashita H., Sakagami H., Gresik E.W. EGF-stimulated signaling by means of PI3K, PLCgamma1, and PKC isozymes regulates branching morphogenesis of the fetal mouse submandibular gland. Developmental Dynamics 2003, 227:216-226.
28. Leivo I., Jee K.J., Heikinheimo K., Laine M., Ollila J., Nagy B., Knuutila S. Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation. Cancer Genetics and Cytogenetics 2005, 156:104-113.
29. Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A., Smith P.D., Cook S.J. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Science Signaling 2011, 4:ra17.
30. Lujan B., Hakim S., Moyano S., Nadal A., Caballero M., Diaz A., Valera A., Carrera M., Cardesa A., Alos L. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. British Journal of Cancer 2010, 103:510-516.
31. Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science 2012, 335:936-941.
32. Melnick M., Jaskoll T. Mouse submandibular gland morphogenesis: a paradigm for embryonic signal processing. Critical Reviews in Oral Biology and Medicine 2000, 11:199-215.
33. Melnick M., Chen H., Zhou Y.M., Jaskoll T. Interleukin-6 signaling and embryonic mouse submandibular salivary gland morphogenesis. Cells, Tissues, Organs 2001, 168:233-245.
34. Melnick M., Chen H., Min Zhou Y., Jaskoll T. The functional genomic response of developing embryonic submandibular glands to NF-kappa B inhibition. BMC Developmental Biology 2001, 1:15.
35. Melnick M., Chen H., Zhou Y., Jaskoll T. Embryonic mouse submandibular salivary gland morphogenesis and the TNF/TNF-R1 signal transduction pathway. Anatomical Record 2001, 262:318-330.
36. Melnick M., Mocarski E.S., Abichaker G., Huang J., Jaskoll T. Cytomegalovirus-induced embryopathology: mouse submandibular salivary gland epithelial-mesenchymal ontogeny as a model. BMC Developmental Biology 2006, 6:42.
37. Melnick M., Phair R.D., Lapidot S.A., Jaskoll T. Salivary gland branching morphogenesis: a quantitative systems analysis of the Eda/Edar/NFkappaB paradigm. BMC Developmental Biology 2009, 9:32.
38. Melnick M., Abichaker G., Htet K., Sedghizadeh P., Jaskoll T. Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesis. Experimental and Molecular Pathology 2011, 1:400-410.
39. Melnick M., Sedghizadeh P.P., Allen C.M., Jaskoll T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Experimental and Molecular Pathology 2012, 92:118-125.
40. Mocellin S., Rossi C.R., Pilati P., Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine & Growth Factor Reviews 2005, 16:35-53.
41. Nichols W.G., Boeckh M. Recent advances in the therapy and prevention of CMV infections. Journal of Clinical Virology 2000, 16:25-40.
42. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Experimental Cell Research 2010, 316:1324-1331.
43. Poulikakos P.I., Solit D.B. Resistance to MEK inhibitors: should we co-target upstream?. Science Signaling 2011, 4:pe16.
44. Raser J.M., O'Shea E.K. Noise in gene expression: origins, consequences, and control. Science 2005, 309:2010-2013.
45. Rozenblatt-Rosen O., Deo R.C., Padi M., Adelmant G., Calderwood M.A., Rolland T., Grace M., Dricot A., Askenazi M., Tavares M., Pevzner S.J., Abderazzaq F., Byrdsong D., Carvunis A.R., Chen A.A., Cheng J., Correll M., Duarte M., Fan C., et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 2012, 487:491-495.
46. Saederup N., Lin Y.C., Dairaghi D.J., Schall T.J., Mocarski E.S. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:10881-10886.
47. Sanchez V., Spector D.H. Subversion of cell cycle regulatory pathways. Current Topics in Microbiology and Immunology 2008, 325:243-262.
48. Schleiss M.R. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infectious Disorders Drug Targets 2011, 11:449-465.
49. Schwarz S., Stiegler C., Müller M., Ettl T., Brockhoff G., Zenk J., Agaimy A. Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 2011, 58:557-570.
50. Specht D. Probabilistic neural network for classification, mapping, or associative memory. Proceeding of the IEEE International Conference on Neural Networks 1988, 1:525-532.
51. Specht D., Shapiro P. Generalization accuracy of probabilistic neural networks captured with back-propagation networks. Proceeding of the IEEE International Joint Conference on Neural Networks 1991, 1:887-892.
52. Sturm O.E., Orton R., Grindlay J., Birtwistle M., Vyshemirsky V., Gilbert D., Calder M., Pitt A., Kholodenko B., Kolch W. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Science Signaling 2010, 3:ra90.
53. Tirado Y., Williams M.D., Hanna E.Y., Kaye F.J., Batsakis J.G., El-Naggar A.K. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes, Chromosomes & Cancer 2007, 46:708-715.
54. Wagner R.P., Tian H., McPherson M.J., Latham P.S., Orenstein J.M. AIDS-associated infections in salivary gland: autopsy survey of 60 cases. Clinical Infectious Diseases 1996, 22:369-371.
55. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., Ribas A., Li J., Moffat J., Sutherlin D.P., Koeppen H., Merchant M., Neve R., Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
56. Yuan J., Liu X., Wu A., McGonagill P., Keller M., Galle C., Meier J. Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells. Journal of Virology 2009, 83:6391-6403.
57. Zheng Q., Tao R., Gao H., Xu J., Shang S., Zhao N. HCMV-encoded UL128 enhances TNF-α and IL-6 expression and promotes PBMC proliferation through the MAPK/ERK pathway in vitro. Viral Immunology 2012, 25:98-105.